Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta gr ...

Rhode Island Rep. Stephen Casey introduced a House bill on Feb. 27, which was referred to the House Corporations Committee, as reported by CFO Dive. Louisiana Rep. Gerald "Beau" Beaullieu IV pre-filed ...

ABA Committee Urges Inclusion of Alternative Licensure Pathways Language in Accreditation Standards The Standards Committee reviewed Standard 316 in light of the recent developments that several U.S.

HOUSTON, TX, January 15, 2026 (EZ Newswire) -- Mars Materials ("MM" or the Company), a company working to store captured carbon dioxide into everyday products, today announced its selection into Shell ...

Complement-mediated hemolytic uremic syndrome (CM-HUS), commonly referred to as atypical HUS, is a rare thrombotic microangiopathy caused by uncontrolled activation of the alternative complement ...

Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...

Sitting in the guidance counselor’s office enrolling in their core subjects is a rite of passage for everyone who passes through their awkward adolescent schooling experience. For some, their biggest ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...

The last time I spoke about Omeros Corporation (OMER) it was in a Seeking Alpha article entitled "Omeros: FDA Appeal On Nasoplimab And Several 2023 Catalysts On Deck." Since then, it has faced several ...